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Abstract
In eukaryotic cells, surface expression of most type I transmembrane proteins requires translation and simultaneous
insertion of the precursor protein into the endoplasmic reticulum (ER) membrane for subsequent routing to the cell surface.
This co-translational translocation pathway is initiated when a hydrophobic N-terminal signal peptide (SP) on the nascent
protein emerges from the ribosome, binds the cytosolic signal recognition particle (SRP), and targets the ribosome-nascent
chain complex to the Sec61 translocon, a universally conserved protein-conducting channel in the ER-membrane. Despite
their common function in Sec61 targeting and ER translocation, SPs have diverse but unique primary sequences. Thus,
drugs that recognise SPs could be exploited to inhibit translocation of specific proteins into the ER. Here, through flow
cytometric analysis the small-molecule macrocycle cyclotriazadisulfonamide (CADA) is identified as a highly selective human
CD4 (hCD4) down-modulator. We show that CADA inhibits CD4 biogenesis and that this is due to its ability to inhibit co-
translational translocation of CD4 into the lumen of the ER, both in cells as in a cell-free in vitro translation/translocation
system. The activity of CADA maps to the cleavable N-terminal SP of hCD4. Moreover, through surface plasmon resonance
analysis we were able to show direct binding of CADA to the SP of hCD4 and identify this SP as the target of our drug.
Furthermore, CADA locks the SP in the translocon during a post-targeting step, possibly in a folded state, and prevents the
translocation of the associated protein into the ER lumen. Instead, the precursor protein is routed to the cytosol for
degradation. These findings demonstrate that a synthetic, cell-permeable small-molecule can be developed as a SP-binding
drug to selectively inhibit protein translocation and to reversibly regulate the expression of specific target proteins.
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Introduction
CD4 is a type I integral membrane glycoprotein that is
expressed on the surface of thymocytes, T-helper lymphocytes,
and cells of the macrophage/monocyte lineage [1]. It plays a
central role in immune responses but also represents an obligatory
component of the cellular receptor complex for HIV [2,3]. Several
reports demonstrate that down-modulation of surface CD4
protects cells from HIV infection [4–8]. In addition, natural
CD4 down-modulation by memory CD4+ T cells in vivo protects
African green monkeys from developing AIDS after infection with
simian immunodeficiency virus (SIV), while maintaining the
immunological functions normally attributed to CD4+ T cells
[9]. Reduction in surface CD4 can be elicited by several factors
that interfere with its translation or intracellular trafficking
(reviewed in [10]). Phorbol esters are known to induce CD4
endocytosis through serine phosphorylation of the cytoplasmic tail
of CD4 [11]. The concerted action of the three HIV-1 proteins
Nef, Env, and Vpu results in a complete removal of CD4 from the
surface of HIV infected cells through (i) enhanced routing of CD4
to the endoplasmic reticulum (ER) degradation pathway [12,13]
and (ii) activated endocytosis and lysosomal degradation [14,15].
Surface expression of type I transmembrane (TM) proteins, such
as CD4 receptors, requires translation of precursor proteins and
their insertion into the ER membrane for subsequent routing to
the cell surface. This co-translational translocation pathway begins
when a hydrophobic N-terminal signal peptide (SP) on the nascent
protein emerges from the ribosome and is recognized by the signal
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recognition particle (SRP). This complex of ribosome, nascent
chain, and SRP is then targeted to the ER membrane via the
interaction between SRP and its membrane receptor. Subse-
quently, the ribosome tightly binds to the Sec61 complex in the
ER-membrane, a protein-conducting channel composed of the
membrane proteins Sec61a, Sec61b, and Sec61c. Finally, the
ribosome continues the translation and the elongating polypeptide
chain moves directly from the ribosome exit tunnel into the
associated membrane channel. When the TM domain within the
nascent polypeptide chain reaches the Sec61 complex, the channel
opens laterally and the membrane anchor is released into the lipid
bilayer (reviewed in [16,17]). Simultaneously with the transloca-
tion of the polypeptide chain, cleavage of the signal sequence
occurs at the luminal side of the ER together with other possible
modifications such as N-glycosylation and proper folding of the
polypeptide.
A screen for anti-HIV drugs led to the identification of CADA,
a cyclotriazadisulfonamide with broad spectrum antiviral activity
against laboratory strains and clinical isolates of HIV-1, as well as
HIV-2 and SIV [18,19]. The anti-HIV activity of CADA and its
analogues correlated with their ability to down-modulate cell
surface CD4 expression [8]. In the present study, we focused on
the mechanism of action and molecular target of CADA. We
demonstrate that CADA inhibits CD4 biogenesis during the early
translational steps. More specifically, we show that (i) CADA
selectively binds to the SP of human CD4 (hCD4), (ii) CADA
prevents the growing CD4 polypeptide from entering the lumen of
the ER, (iii) the SP of hCD4 is first inserted into the translocon
channel with its N-terminus facing the lumen of the ER (Nlum/
Ccyt) before an obligate inversion into a Ncyt/Clum topology takes
place, and (iv) CADA locks the SP of hCD4 in an intermediate
position during inversion and prevents further translocation of the
polypeptide chain into the ER lumen.
Results
CADA Selectively Down-modulates Human CD4
To evaluate the effect of CADA on CD4 expression, different
cells were treated with the compound under various conditions
(Figures 1 and S1). CADA induced a dose-dependent down-
modulation of hCD4 regardless of the cell background in which it
was expressed, i.e., in primary T-cells and T-cell lines that express
the receptor naturally, as well as in transfected cells stably
expressing CD4 (Figure 1B–1D). This down-modulating effect
appeared to be reversible (Figure 1G), and selective for CD4: in a
set of 14 different surface receptors CADA inhibited only CD4
(Figure 1E and 1F). The sensitivity of CD4 for CADA was species-
specific: the compound did not affect the expression of mouse
CD4, whereas primary T-cells from macaques responded to the
compound in a similar way to human T-cells (Figure 1D). Thus,
CADA selectively and reversibly down-modulates CD4 of primate
origin in a dose-dependent manner.
CADA Inhibits the Biogenesis of Human CD4 in a Signal
Peptide-Dependent Way
To elucidate how CADA interferes with CD4 protein expres-
sion, we analyzed the impact of CADA on the life cycle of CD4. A
kinetic study with CADA and the phorbol ester PMA, a drug
known to induce rapid endocytosis and degradation of surface
CD4 [11], suggested an effect of CADA on CD4 translation or
transport to the cell surface. As shown in Figure 1H, the
appearance of newly synthesized CD4 molecules at the surface
was prevented by CADA. To test directly whether CADA
interferes with the de novo synthesis of CD4 we performed
pulse-chase experiments followed by immunoprecipitation for
CD4. CADA profoundly inhibited CD4 synthesis in CHO.CD4+
cells as indicated by the absence of this protein band in CADA-
treated samples (Figure 2A and 2B). Although CADA strongly
affected CD4, analysis of the total cellular protein extract revealed
no general inhibition of protein synthesis (Figure 2A, lanes 3 and
4). We further analyzed this CD4-specificity of CADA by
examining protein synthesis in different cellular compartments.
Both cytosolic and membrane fractions were investigated in CD4-
negative and CD4-positive CHO cells. The expression of cytosolic
proteins was not altered by CADA-treatment, both in the absence
or presence of CD4 (Figure 2C and 2D). In contrast, addition of
the translation elongation inhibitor cycloheximide (CHX) resulted
in an almost complete protein shut-down. Interestingly, CADA
seemed not to affect other membrane proteins in the CD4-
negative cells. Also, a similar membrane protein expression pattern
was observed in DMSO and CADA-treated CD4+ CHO cells,
except for one protein band migrating around 80 kDa. As this
protein band could not be detected in the CD4-negative cells, we
concluded that the affected protein was most likely CD4-YFP, an
80 kDa fusion protein that is stably and highly expressed in these
CHO cells. The significant reduction in synthesis of membrane-
associated proteins in CADA-treated CD4+ CHO cells (Fig-
ure 2D) can be ascribed to the complete block of CD4-YFP
production. To isolate the glycosylated surface proteins from the
membrane fraction that contains proteins not only from the
surface membrane but also from different intracellular organelles
and export pathways, we used Concanavalin A (ConA) agarose
beads. Again, CD4-YFP was strongly inhibited by CADA,
whereas the expression of other glycosylated membrane proteins
was not affected (Figure 2E). In addition, CADA did not inhibit
the secretion of proteins into the culture medium (Figure 2E).
Similar observations were made in other CADA-treated cells, such
as U87 and SupT1 (Figure S2). Finally, down-modulation of CD4
Author Summary
All cells are highly crowded with proteins that, once
synthesized, have to reach their proper subcellular location
in order to maintain the cellular homeostasis. Approxi-
mately 30% of the proteome needs to be sorted from the
cytosol and inserted into, or transported through, biolog-
ical membranes. For proteins sorted via the secretory
pathway, an important step is the translocation into a
cellular compartment called the endoplasmic reticulum
(ER). The cell uses an elegant way to discriminate proteins
that need to be translocated into the ER from those that
have to reside in the cytosol by scanning for the presence
of an N-terminal ER-entry tag. Although these tags, called
signal peptides, have a common structure, they each
contain a unique hydrophobic peptide sequence. In this
work, we describe how a small chemical drug, CADA, can
bind to one specific signal peptide present in the human
peptide orientation in the translocation channel located in
the ER membrane, CADA prevents CD4 translocation into
the ER lumen. As a consequence, the CD4 protein is not
properly synthesized and routed to the cell surface,
resulting in a clear reduction in the amount of surface
CD4, a membrane protein found on immune cells, and
implicated in HIV-infection and other diseases. We believe
that other drugs can be designed to selectively regulate, in
a similar way, ER translocation of specific target proteins.
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CD4 pre-protein. We show that by influencing the signal
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Figure 1. CADA selectively and reversibly down-modulates human CD4 in a dose-dependent way. (A) Structure of CADA, molecular
weight (MW)= 618. (B) U87 cells stably expressing hCD4 were treated with a serial 1:10 dilution of CADA. After 24 h, cell lysates were analyzed by
immunoblotting with anti-CD4 or anti-clathrin antibodies. A non-transfected control is included (first lane). Molecular mass is in kDa. (C) Dose-
response curve showing the effect of CADA on hCD4 expression in the human T-lymphoid cell line SupT1 expressing CD4 naturally (circles; IC50 is
0.55 mM), in the stably transfected human U87 glioblastoma (crosses, IC50 is 0.32 mM) and Hela epithelial cervical cancer cells (triangles, IC50 is
0.27 mM). Surface CD4 expression levels were normalized to non-treated controls as determined by flow cytometry (n$4). (D) Dose-response curve
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occurred post-transcriptionally, because CD4 messenger RNA
levels were not altered by the compound (Figure S1F). From these
data, we concluded that CADA has a high selectivity for the
protein synthesis of hCD4.
Next, we established which domain of CD4 is required for drug
sensitivity by investigating C-terminal deletion mutants (Figure 3).
Deletion of the cytosolic tail of CD4, which is involved in signal
transduction and endocytosis of the receptor [11,20], did not affect
its sensitivity to CADA (Figure 3A, mutant hCD4-426). Exchang-
ing the extracellular D3, D4, and transmembrane (TM) domains
of CD4 with a related type I TM protein such as the alpha chain of
CD8, expression of which is not affected by CADA (Figure 1F),
failed to prevent CADA-induced down-modulation (Figure 3A,
mutant hCD4-CD8). Furthermore, human/mouse chimaeric
fusion constructs excluded a potential role for the immunoglob-
ulin-like domains D1 and D2 of hCD4 in CADA-sensitivity. In
agreement with primary murine T-cells (Figure 1D), wild-type
mouse CD4 (mCD4 WT) did not respond to the down-modulating
activity of CADA, whereas hCD4 containing either mouse D1 or
mouse D2 did (Figure 3B). These data narrowed down the
CADA-sensitive region of hCD4 to the N-terminal SP and the first
seven N-terminal residues of the mature protein, as this is the only
remaining fragment of hCD4 common to all CADA-susceptible
constructs (Figures 3 and S1E).
CADA Dose-Dependently Inhibits Translocation of
Human CD4
Previous experiments demonstrated an inhibitory effect of
CADA on the expression of membrane-anchored proteins that
contained the SP of hCD4. However, removal of the TM domain
of CD4 did not diminish the sensitivity of the protein to CADA
(Figure 4B), showing that CADA-susceptibility is not membrane
anchor-dependent. Therefore, in our further study we also
included smaller secreted proteins (Figure 4A).
In general, precursors of type I TM proteins (e.g., CD4) contain
an amino-terminal SP that is involved in the early steps of
biogenesis such as targeting of the nascent polypeptide to the ER
membrane for co-translational translocation [21,22]. To deter-
mine how CADA interferes with CD4 synthesis, translation and
translocation of CD4 were analyzed in vitro using cell-free rabbit
reticulocyte lysate with or without pancreatic rough microsomes
(RMs). In the absence of RMs, translation of full length and
truncated hCD4 was unaffected by CADA (Figure 4C, lanes 1 and
2, open arrowhead). However, in the presence of RM, transloca-
tion of hCD4 into the RM lumen was markedly inhibited by
CADA as indicated by a reduction in glycosylated WT hCD4
(Figure 4C, lanes 4 and 7, star) and SP-cleaved truncated hCD4
(Figure 4C, lanes 4 and 7, solid arrowhead) that were resistant to
degradation by added proteases (Figure 4C, lanes 5 and 8). In
agreement with the in cellulo results of Figure 4B, the in vitro
translocation of full length (hCD4 WT) and truncated secreted
(hCD4-201) CD4 was dose-dependently inhibited by CADA
(Figure 4D). In contrast, the translocation of two control
molecules, mCD4-186 and bovine pre-prolactin (pPL), was not
affected by CADA at any concentration tested (Figure 4D and
4E).
We next prepared two chimaeric constructs (Figure 4A) in
which the mature domain of pPL was fused either directly to the
SP of hCD4 ([hCD4]-pPL) or to the seventh residue of mature
hCD4 ([hCD4]-(7)-pPL). Translocation of [hCD4]-pPL was
profoundly inhibited by CADA (Figure 4D and 4E). While this
mutant was slightly less sensitive to the compound than WT CD4,
this confirms that sensitivity to CADA is determined primarily by
the hCD4 SP. However, the presence of seven additional amino
acids of the N-terminal CD4 mature domain enhanced CADA
sensitivity, resulting in dose-dependent translocation inhibitory
levels similar to WT CD4 (Figure 4E, construct [hCD4]-(7)-pPL).
Furthermore, fusing these N-terminal 32 residues of hCD4 to a
non-SP containing yellow fluorescent protein (YFP) resulted in
translocation of a non-CD4 related cytosolic protein into the RM
lumen and full susceptibility to CADA (Figure S3A–S3C). These
data show that inhibition of protein translocation by CADA is
specific to the SP and the first seven N-terminal residues of mature
hCD4.
To investigate if CADA inhibits CD4 translocation into the ER
in vivo, we performed experiments to rescue cytosolic CD4 in
HEK293T cells by inhibiting proteosomal degradation with
MG132. In order to detect all precursor forms of CD4, we
generated an hCD4 construct that contained the simian virus 5
(V5) epitope at the N-terminal end of the mature protein (outlined
in Figure S3E). Only when the cells were treated with the
combination of CADA and the proteasome inhibitor MG132, a
higher molecular form of CD4 could be detected that correspond-
ed to the precursor form of the V5-tagged CD4 (Figure 4F).
Accordingly, for [hCD4]-YFP proteasome inhibition with MG132
also rescued the precursor form in CADA-treated samples (Figure
S3D). These in vivo results indicate that CADA diverts CD4
synthesis towards cytosolic proteosomal degradation.
CADA Binds to hCD4 SP and Interacts Primarily with Its
Hydrophobic H-Region
We then looked for direct interaction between CADA and the
hCD4 SP. Chemically synthesized SPs of hCD4 and mCD4 were
captured on a streptavidin sensor chip and examined by surface
plasmon resonance (SPR). Selective and dose-dependent binding
of CADA to hCD4 SP was observed, and almost no binding to
mCD4 SP (Figures 5A and S4A). Also, CADA did not show
interaction with the SP of bovine pPL (Figure S4C). As a control,
SRP interaction with the SPs was evaluated and revealed equal
binding profiles of SRP to human and mouse SP, thus excluding
showing the selective effect of CADA on primate CD4. Primary T-cells isolated from the blood of humans, macaques, or mice were stimulated with
2 mg/ml phytohaemagglutinin (PHA) and treated with CADA for 3 days. Next, cells were stained for surface CD4 and analyzed by flow cytometry. Data
represent mean values from two different donors. (E) Human T-lymphoid MT-4 cells were treated with control medium or 3.2 mM CADA. After 24 h,
cell surface proteins were quantified by flow cytometry. DC-SIGN expression was determined in stably DC-SIGN-transfected CEM cells. Protein
expression levels were normalized to non-treated controls (three independent experiments of 10,000 analyzed cells each). *p,0.01. (F) Flow
cytometry analysis of surface proteins in transfected HEK293T cells treated with CADA for 48 h. Protein expression levels were normalized to non-
treated controls (three independent experiments). *p,0.01. (G) CD4 down-modulation by CADA is reversible. Primary human T-cells isolated from the
blood of healthy donors were stimulated with 2 mg/ml PHA and treated with CADA for 3 days. Next, cells were washed and given control medium for
another 6 days. Cells were harvested at specified time points and analyzed for surface CD4 expression by flow cytometry. Data represent mean values
from two different donors. (H) Kinetics of CD4 down-modulation showing a slow but steady removal of surface CD4 with CADA, and a fast but
transient decrease in CD4 with PMA. Graph represents flow cytometric surface CD4 analysis of CHO cells stably expressing hCD4 either treated with
16 mM CADA or 0.16 mM PMA, or treated simultaneously with CADA and PMA. Surface CD4 expression levels were normalized to non-treated controls
(n$2).
doi:10.1371/journal.pbio.1002011.g001
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Figure 2. CADA specifically inhibits the biogenesis of human CD4. (A, B) CADA inhibits the biosynthesis of CD4. CD4+.CHO cells were washed
and kept in methionine and cysteine-free medium in the presence or absence of 16 mM CADA for 45 min before exposure to [35S]methionine/
cysteine (Met/Cys) for 30 min. Pulsed-labelled cells were then washed, lysed, and analyzed directly (A) or incubated in normal medium for up to 4 h
(chase) in the presence or absence of 16 mM CADA (B). At specified time points cell lysates were immunoprecipitated for CD4. The flow through
fraction (FT) of the CD4-immunoprecipitated samples is also presented. Note that the weaker CD4 bands in the control samples at longer chase time
points are the result of the high turnover of hCD4 in CHO cells. Molecular mass is in kDa. (C–F) CD4 negative and stably CD4-YFP transfected CHO
cells were pretreated with CADA (5 mM) or DMSO for 1 h before starvation in Met/Cys free medium with CADA, DMSO, or 50 mg/ml CHX. Cells were
pulsed for 30 min, washed, and incubated in fresh medium without serum for 90 min. After collection of supernatant proteins (Media) cells were first
permeabilized with digitonin buffer to obtain the cytosolic cell fraction before lysis in NP-40 buffer to collect the membrane proteins. Membrane
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non-functionality of mSP or insufficient peptide-coupling to the
chip (Figures 5B and S4B). In addition, the lack of hCD4 SP
binding by the structural analog MFS105 (Figure 5C), a CADA-
derivative with no CD4 receptor down-modulating activity (Figure
S4E) [8], further strengthens the selectivity of CADA for hCD4
SP.
SPs display a general structure consisting of three regions: a
(mostly) positively charged N-terminus (N-region), a central
hydrophobic alpha helical region (H-region), and a more polar
C-terminal part (C-region) that includes the SP cleavage site [23].
On the basis of the unresponsiveness of mouse CD4 to CADA
(Figures 1D, 3B, 4D, and 4E), we generated human/mouse
chimaeric constructs with exchanged SP subregions in order to
analyze the contribution of each subregion of hCD4 SP to CADA-
susceptibility (Figure 5D). Exchanging the N-region of the SP
(construct [mhh]-hCD4) slightly decreased the sensitivity of CD4
to CADA, as analyzed by flow cytometry (Figure 5E). A stronger
reduction in susceptibility was observed when the C-region of mSP
and the first seven N-terminal residues of mature mCD4 were
inserted in hCD4 (Figure 5E, construct [hhm]-hCD4). Swapping
fractions were further incubated with Concanavalin A (ConA) agarose beads (Glycosylated). Molecular mass is in kDa. (D) Quantification of 35S
incorporation in (C) by scintillation counting (n= 4). NS, not significant; *p,0.01. (F) ConA fraction from a repeat experiment with CHO.CD4+ cells
treated with DMSO or CADA. Note that the expression of CD4-YFP (,80 kDa) is clearly reduced by CADA-treatment (indicated by arrow).
doi:10.1371/journal.pbio.1002011.g002
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Figure 3. CADA inhibits the expression of human CD4 in a signal peptide-dependent way. (A) Schematic representation of the hCD4 C-
terminal deletion constructs used. Numbers represent the corresponding amino acids of the pre-protein. The N-terminal SPs are indicated by a black
rectangle. In mutant hCD4-426 the intracellular C-terminal domain has been removed. Construct hCD4-CD8 is composed of the D1 and D2 domains
of hCD4 fused to the membrane-bound alpha chain of hCD8. CD42 A2.01 human T-cells stably expressing hCD4WT, hCD4-426, or hCD4-CD8 were
treated for 48 h with control medium or CADA (8 mM) and stained with anti-CD4 antibody to determine surface expression levels of WT or mutant
CD4 by flow cytometry. Graph shows relative receptor expression levels of CADA-treated cells as compared to non-treated controls. (B) Schematic
representation of the human/mouse chimaeric constructs used. Numbers represent the corresponding amino acids of the pre-protein. The N-terminal
SPs are indicated by a black rectangle. The human/mouse chimaeric constructs are C-terminally fused to YFP for ease of flow cytometric detection.
Construct hCD4-mD1 is composed of hCD4 in which the D1 region is replaced by the corresponding D1 domain of mouse CD4. It still contains the SP
of hCD4 and the first seven residues of mature hCD4. Construct hCD4-mD2 is composed of hCD4 in which the D2 is replaced by the corresponding
D2 domain of mouse CD4. HEK293T cells were transiently transfected with the expression plasmids and left either untreated or treated with CADA for
24 h. YFP fluorescence was determined and normalized to non-treated controls.
doi:10.1371/journal.pbio.1002011.g003
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Figure 4. CADA dose-dependently inhibits co-translational translocation of human CD4. (A) Schematic representation of the constructs
used. Numbers represent the corresponding amino acids of the pre-protein. The N-terminal SPs are indicated by a black rectangle. The star represents
the N-glycosylation site in full length hCD4. (B) HEK293T cells were transiently transfected with the expression plasmids and left either untreated or
treated with CADA for 48 h. Receptor expression levels were determined by flow cytometry and normalized to non-treated controls (n$3). NS, not
significant. (C) Transcripts encoding full length (hCD4 WT) and truncated (hCD4-201) hCD4 were translated in the presence of [35S]methionine and,
where indicated, RMs and/or CADA (15 mM). Equal aliquots of the translated material were left untreated or treated with PK in the presence or
absence of Triton X-100 (Triton). Samples were separated by SDS-PAGE and analyzed by autoradiography. The positions of precursor (open
arrowhead), signal-cleaved (solid arrowhead), and glycosylated (asterisk) species are indicated. Of note is the lower appearance of the PK-protected
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the hydrophobic H-region had a major negative impact on the
sensitivity to CADA (Figure 5E, construct [hmh]-hCD4). Revers-
ibly, insertion of the hydrophobic alpha helix of hCD4 SP into
CADA-insensitive SPs, such as those of murine CD4 or bovine
pPL, significantly enhanced their responsiveness to CADA (Figure
S5C and S5D). In addition, the different inhibitory levels of
CADA on surface expression of the human-murine chimaeras
could be linked to different degrees in ER translocation inhibition
(Figure S5A and S5B). Although a more than 10-fold reduction in
CADA-activity was noted in the in vitro assay as compared to the
in cellulo data (Figure 5E versus S5B), the chimaeras responded to
CADA in the same relative order. These data suggest contribu-
tions from all three hCD4 SP subregions to CADA-sensitivity, but
show a crucial role for the hydrophobic H-region.
CADA Inhibits the Translocation of [CD4]-pPL Nascent
Peptide Chains at a Post-Targeting Step
To identify the step at which CADA interferes with the
translocation of hCD4, we analyzed the targeting and transloca-
tion of [CD4]-pPL nascent chains. Transcripts lacking a stop
codon were truncated at sequential sites in the mature domain
(Figure 6A) and translated in vitro. Via an intact peptidyl-tRNA
bond the nascent chains remain attached to the ribosomes and are
synchronized at a defined length. Addition of pancreatic RMs will
result in docking of the different ribosome-nascent chain
complexes (RNCs) to the ER membranes, giving translocation
intermediates that represent static snapshots of the movement of
the SP within the translocon channel. Subsequently, the nascent
chains are released from membrane-bound ribosomes by puro-
mycin, allowing for a controlled translocation into the ER lumen.
Nascent chains of 80 residues (80-mers) were translated in the
absence of RM (Figure 6B, left panel, first lane). These chains are
bound to the ribosome as peptidyl-tRNAs with about 30 residues
buried inside the ribosome. Protease treatment of these RNCs will
degrade the N-terminal part of the peptide that is exposed to the
cytosolic compartment (about 50 residues), and will generate a
faster migrating protein band on the gel (Figure 6B, lane 6).
Addition of RM to the nascent chains will allow for targeting of the
RNCs to the membrane and insertion of the SP into the
translocon channel. If well-targeted, nascent chains will be
shielded from exogenous protease because of a tight interaction
between the ribosome and the translocon after transfer from SRP
[24,25], and appear as intact RNCs after proteinase K (PK)
treatment. Equal protease-protected peptidyl-tRNA bands were
observed in control and CADA samples, ruling out an inhibitory
activity of CADA on targeting and transfer of the nascent chains to
the translocon (Figures 6B, lanes 7 and 8, arrow). Addition of
puromycin to the targeted chains induced the release of the
nascent chains from the ribosome, with subsequent translocation
of the peptides into the PK-protected RM lumen and cleavage of
the SP (Figure 6B, lanes 4 and 9, solid arrowhead). However, in
the presence of CADA, very few cleaved species were observed
(Figure 6B, left panel, lane 5, solid arrowhead), indicating a
profound inhibition by CADA on the co-translational transloca-
tion of pPL species that contained the SP of hCD4 but not of those
with the SP of WT pPL (Figure 6B, left and right panel,
respectively). This inhibition was also dose-dependent (Figure 6C).
Translocation inhibition by CADA was observed at all chain
lengths, but was most effective on nascent chains up to 80 residues
(Figure S7).
Remarkably, we could delay the administration of CADA to the
membranes until targeting was completed. A similar inhibitory
effect on the translocation of 80-mers was recorded when the
compound was applied to the RM before targeting or to the
RNC/RM mixture 15 minutes after initiation of targeting
(Figure 6D). Taken together, these results indicate that CADA
acts at a step after the targeting and transfer of the nascent chains
to the translocon, but before the growing peptide chain has
reached the luminal side of the membrane.
CADA Interferes with the Topology Inversion of hCD4 SP
Although N-terminal signal sequences are generally considered
to insert in a tail-first, hairpin-looped topology [26,27], hydro-
phobic sequences can also enter the translocon in a head-first
configuration or reorient within the translocon channel [28–32].
To determine if CADA might have a role in changing the topology
of the SP during translocation, we introduced a diagnostic N-
glycosylation site at the N-terminus of the SP (Figure 7A). Head-
first N-terminal translocation of the SP will give rise to glycosylated
species, whereas tail-first C-terminal orientation will result in SP-
cleaved forms.
The hCD4 SP was extended with 17 residues based on a
construct used in other studies [33,34], and either contained or
lacked (control) an N-linked-glycosylation site (Figure 7A). Full
length proteins with the extended hCD4 SP translocated well,
irrespective of the presence of the glycosylation site, and responded
to CADA in a dose-dependent way (Figure S8A). Through analysis
of nascent chains we investigated if and when head-first
translocation occurred, and determined the stepwise movement
of the extended SP within the translocon (Figure 7B). At shorter
truncations (i.e., 17+58-m), a substantial fraction of the nascent
chains were glycosylated, indicating that targeting may begin with
the N-terminus of the SP in the ribosome/translocon complex
facing the RM lumen. At this chain length, the binding of the
RNC to the translocon was already highly stable as evidenced by
its high-salt resistance (Figure S8E). Elongation of the mature part
of the polypeptide with four residues (17+62-m) resulted in a
profound increase in glycosylated RNCs (Figure 7B, second lane
of third panel, star). At longer truncations, the glycosylation
efficiency decreased gradually and was almost undetectable for the
17+88-mer. Interestingly, administration of CADA to the RNCs
had very little effect on the N-terminal glycosylation of the shorter
chains (17+58-m) and the high-salt resistant binding of the RNC to
the translocon (Figure 7B, third lane of second panel, and Figure
S8E). However, the inhibitory activity of CADA increased
significantly when the C-terminus of the polypeptide was
extended, and resulted in non-detectable glycosylation levels for
chains with a minimum length of (17+71) residues (Figure 7B).
glycosylated form of hCD4 WT (lane 5) compared to the non-PK form (lane 4), which is due to proteolytic cleavage of the 38 amino acid cytoplasmic
domain, resulting in a smaller and faster migrating fragment. (D) As in (C), except that a 1:10 serial dilution of CADA was used. (E) Translocation data
of (D) quantified by phosphorimager analysis. The translocation efficiencies, at 15 mM CADA, normalized to control are indicated (mean values of at
least three experiments). (F) Cytosolic degradation of precursor hCD4 in CADA-treated cells. HEK293T cells were transiently transfected with V5-
tagged hCD4, treated with CADA (10 mM) and/or the proteasome inhibitor MG132 (200 nM). Cells were lysed in NP-40 buffer and analyzed by
immunoblotting for CD4 with anti-V5 antibody. For the cell loading control, an anti-actin antibody was used. The predicted molecular mass for the
SP-cleaved sCD4 (V5sCD4) was 22 kDa, whereas that of the precursor form ([hCD4]-V5sCD4) was 25 kDa. Molecular mass is in kDa. Similar data were
obtained with 2 mM CADA. One representative experiment out of two is shown.
doi:10.1371/journal.pbio.1002011.g004
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Figure 5. CADA binds to the signal peptide of human CD4 and interacts primarily with its hydrophobic H-region. (A) Binding of CADA
to the SP of human but not to mouse CD4. Chemically synthesized peptides composed of the signal sequence and eight N-terminal residues of
mature CD4, plus a PEG11 linker and a biotinylated lysine at the C-terminus, were captured on a streptavidin C1 chip for SPR analysis. The chip density
was 84 and 153 resonance units (RUs) for human and mouse SP, respectively. Graph shows interaction of CADA (160 mM) to hCD4 SP (green) but not
to mCD4 (blue). (B) As in (A), but for the binding of SRP to the SPs. The chip density was between 120 and 130 resonance units (RUs). Graph shows
dose response of SRP (nM) to hCD4 SP (green). Similar binding of SRP (25 nM) was observed for mouse CD4 SP (blue). (C) The inactive CADA-analog
MFS105 (MFS, red line) did not bind to the hCD4 SP (up to 1,000 mM), whereas for CADA a dose-dependent binding was measured (black lines). The
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Notably, administration of CADA to the 17+71-mers resulted in a
loss of the high-salt resistant binding of the RNC to the translocon
(Figure S8E), suggesting that with the compound the positioning of
the nascent chain in the channel was altered so that the peptide
tether could allow the ribosome to dissociate from the channel.
Analysis of the puromycin-treated samples revealed a similar N-
terminal glycosylation pattern for the released chains as for the
intact RNCs (Figure 7C and 7D). Again, the inhibitory activity of
CADA on N-terminal glycosylation gradually increased with
growing chain length for chains up to (17+71) residues
(Figure 7D). Breaking the peptidyl-tRNA bond with puromycin
also allowed for translocation of the chains into the RM lumen
with subsequent SP cleavage. SP-cleaved species were hardly
detectable for the shorter chains, irrespective of the presence of a
glycosylation site (Figure 7C and 7E, blue line). However,
translocated SP-cleaved chains that were PK-protected first
appeared for the 17+80-mers, i.e., a chain length at which a
profound decrease in N-terminal glycosylation was noted (Fig-
ure 7C–7E). This suggests that at this specific chain length the SP
is mainly positioned in the hairpin-looped topology with the C-
terminus facing the RM lumen. In accordance with the data from
the WT SP-containing chains (Figure S7B), maximum C-terminal
translocation and SP-cleavage were noted for the 17+80-mers,
thus when the distance from the SP cleavage site to the ribosome
peptidyltransferase centre (PTC) had reached a chain length of
about 55 amino acids. Further extension of the polypeptide chain
diminished the C-terminal translocation efficiency that was
consistently blocked by CADA (Figure 7E). Notably, for the 17+
80-mers CADA strongly inhibited both the (weak) N-terminal
glycosylation and the C-terminal translocation and SP-cleavage
with equal efficiency, in a dose-dependent manner (Figure S8C
and S8D).
These results together show that the nascent chains need a
minimum length in order for CADA to exert its inhibitory effect
on glycosylation, whereas at all lengths where SP-cleavage can be
observed translocation with SP-cleavage is inhibited. Thus, on one
hand, CADA hinders vertical positioning of the polypeptide with
the N-terminus faced to the ER lumen for efficient glycosylation
and, on the other hand, disturbs the completion of SP inversion for
a hairpin-looped structure that can be SP-cleaved (Figure 7F).
This suggests that in the presence of CADA the SP is held in a
folded conformation in the translocon channel, so that the
polypeptide is prevented from reaching the luminal side of the ER.
Discussion
In this study we have characterized CADA, a small-molecule
HIV entry inhibitor as, to our knowledge, the first SP-binding
drug that selectively inhibits hCD4 protein translocation into the
ER in a SP-dependent way.
CD4 is a type I membrane protein expressed on the surface of a
subset of immune cells [1]. Sorting of this protein to the plasma
membrane requires that the CD4 pre-protein contains a cleavable
SP, an obligatory component for protein targeting to the ER
through co-translational translocation. This synthetic pathway
begins when a hydrophobic N-terminal SP emerges from the
ribosome, is recognized by the SRP, and targets the whole RNC to
the ER membrane so that the emerging polypeptide is inserted
into the Sec61 translocon channel [16,17]. Simultaneously with
the translocation of the polypeptide chain, cleavage of the SP
occurs at the luminal side of the ER. Here, we revealed that
targeting of hCD4 to the ER is initiated with a head-first N-
terminal insertion (Nlum/Ccyt) of the SP in the translocon, before it
inverts into an obligate Ncyt/Clum topology necessary for SP
cleavage during C-terminal translocation. Thus, initial insertion of
hCD4 SP in the channel occurs differently from the more widely
accepted hairpin positioning (Ncyt/Clum) of cleavable N-terminal
signals [26,27,35]. Head-first topology of non-cleavable N-
terminal sequences has been proposed by the Spiess group for
signal-anchor (SA) sequences that anchor the polypeptide in the
bilayer [29–31,36]. Recently, a detailed study with an N-terminal
type II SA sequence confirmed the head-first insertion of the SA
into Sec61a before inversion from type I to type II topology takes
place [32]. It is plausible that cleavable N-terminal SPs insert and
invert in a similar way as type II SA sequences. Moreover, for a
relatively short nascent polypeptide that is C-terminally attached
to the ribosome PTC, the first possible way for the N-terminal SP
to interact with the translocon is most likely a head-first (Nlum/
Ccyt) orientation. Initial positioning of signal sequences may also
be directed by interaction with cytosolic chaperones other than
SRP, and translocon-associated proteins. Recently, Sec62 has
been found to mediate the orientation of SA proteins depending
on the hydrophobicity of the SA sequence [37]. It would be
interesting to explore if there are other type I membrane proteins
with initial Nlum/Ccyt insertion and to investigate if the factors that
determine this early positioning of cleavable SP are different from
those reported for N-terminal SA sequences.
Reorientation of SA sequences is driven by flanking charges
according to the positive-inside rule [38,39] and inhibited by
increased hydrophobicity of the SA sequence [40]. For hCD4 the
two adjacent lysine residues immediately down-stream of the SP
cleavage site might overrule the more dispersed positive charge of
the N-domain (two arginine residues R3 and R8) and initially
orient the SP according to this positive-inside rule with its C-
terminus to the (negatively charged) cytosolic side of the
membrane. In line with the canonical SA derived from the first
TM segment of aquaporin 4 [32], hCD4 SP initiates ER targeting
at a nascent chain length of 58 residues, when the size of the
polypeptide between the SP C-terminus and the PTC is about 33
residues. Inversion of hCD4 SP and translocation of its C-terminal
segment with SP-cleavage were observed upon lengthening the
polypeptide chain (at its C-terminus) with 22 amino acids, a stretch
theoretically long enough to span the bilayer membrane and thus
to allow for a hairpin looped positioning of the SP. For our study
we extended the N-terminal hydrophilic domain of hCD4 SP with
17 residues as this was the minimum length required to obtain
optimal glycosylation of the N-terminus (Figure S9A–S9C),
because of the distance between the active site of the oligosac-
charyl transferase complex and the inner bilayer of the ER
membrane [41]. Extension of the N-domain of SA sequences with
more than 20 residues can change their signal insertion behaviour,
but in favour of C-terminal insertion [36]. Our extended hCD4 SP
chip density was 95 RUs. For clarity of the figure, only the 500 mM line is shown. Comparable data were obtained in an independent experiment
shown in Figure S4D. (D) Schematic representation of the constructs used. The N-, H-, and C-regions of the SP of hCD4 were exchanged for those of
mouse CD4. Also the first seven N-terminal residues of the mature protein were swapped as indicated. The residues of hCD4 are depicted in green,
whereas those of mouse CD4 are in blue and underlined. (E) Flow cytometry analysis of HEK293T cells transiently transfected with the expression
plasmids from (D) and left either untreated or treated with CADA for 48 h. Cells were collected and stained for hCD4. CD4 expression levels were
normalized to non-treated controls (n$3). The IC50 values of CADA for each construct are included.
doi:10.1371/journal.pbio.1002011.g005
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Figure 6. CADA inhibits co-translational translocation of hCD4-pPL at a post-targeting step. (A) Schematic representation of the truncated
nascent chains of [hCD4]-(7)-pPL. The nascent chains remain attached to the ribosome through a peptidyl-tRNA bond. The (approximately) 30 residues at
the C-terminus of the polypeptide that are buried inside the ribosome are indicated by a grey rectangle. The SP cleavage site (at residue 25) is also marked.
(B) In vitro translation, targeting, translocation (puromycin-release), and PK digestion of [35S]methionine-labelled [hCD4]-(7)-pPL 80-mers (left panel) andWT
pPL 78-mers (right panel). Intact peptidyl-tRNA bands (NC-tRNA, arrow) are indicated and represent the targeted and PK protected RNCs. Note that the
presence of microsomes (RM) releases some nascent chains (NC) from tRNA in an unproductive way (compare lanes 1 and 2, open arrowhead). The
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did not shift to a preferentially C-terminal translocation with SP-
cleavage (Figure S9D), suggesting that the extended hCD4 SP
preserved the same insertion behaviour as WT SP.
Our data indicated equal targeting efficiencies for control and
CADA-treated nascent chains, making interference of CADA with
SRP-binding less likely. Furthermore, the equal mRNA levels that
were detected in CADA-treated and control cells indicate that the
compound does not induce an mRNA degradation response as has
been observed with defective signal sequence recognition by SRP
[42]. Also, early insertion of the SP into the translocon channel was
not altered by our drug, ruling out inhibition of channel gating by
CADA. The post-targeting translocation inhibition by CADA is
probably related to the obligate inversion of hCD4 SP inside the
translocon. One can expect that the reorientation of the hCD4 SP
from an Nlum/Ccyt into an Ncyt/Clum topology requires a high degree
of flexibility of the SP and the translocation channel to undertake
such a gymnastics, whichmay be compromised after CADA-binding.
Based on the CADA-sensitive chimaeras that contained the
hydrophobic alpha-helix of hCD4 SP, we could attribute a crucial
role to the core hydrophobic domain of the SP and hypothesize
compound binding to this region. In fact, minor changes in this
alpha-helix, such as removing the helix terminator Pro20, could
already reduce CADA-dependency, but introducing this proline
residue at the C-terminal part of the murine ortholog was not
sufficient to render sensitivity to the drug (see Figure S6). However,
not only the central hydrophobic a-helical H-region of hCD4 SP, but
also its C-terminus together with the first residues of the mature
protein was shown to be important for full CADA-sensitivity.
Interaction of CADA with both regions might re-position the SP in
the translocon and profoundly reduce flexibility or alter the balance
between hydrophobic and electrostatic interactions of the SP with the
translocon and the lipid environment [43–45]. Also, post-targeted
folding of a zinc-finger modified pPL has recently been shown to
inhibit co-translational translocation into ER microsomes, indicating
that folding events within the ribosome-Sec61 translocon complex
(RTC) can occur and induce a mechanical block within the RTC that
diverts the nascent chain into the cytosol for degradation [46].
Accordingly, in the presence of CADA the non-translocated CD4
precursor forms are routed to the cytosol for proteasomal degrada-
tion, which also indicates that translocation and not translation of
CD4 is inhibited by the compound.
In our experiments, C-terminal translocation of nascent chains
was determined by SP-cleavage. Inhibition of the signal peptidase
activity could also be interpreted as an inhibition of translocation,
however, CADA did not interfere with the enzymatic activity of
RM-extracted signal peptidase (Figure S9E). Furthermore, both
inhibition of N-glycosylation and SP-cleavage were observed with
the N-terminally extended 80-mers, making it very unlikely that
CADA would inhibit both luminal enzymes that act at distinct
parts of the SP. Therefore, we propose that in the presence of
CADA the SP is held in a folded conformation in the translocon
(presumably at the lateral gate), so that the polypeptide is
prevented from moving through the channel.
The focus of this work was to unravel the mechanism through
which CADA selectively regulates CD4 expression. We show that
CADA selectively inhibits the biogenesis of CD4 in cells without
affecting other membrane or secretory proteins, and that this is
due to its ability to inhibit specifically the co-translational
translocation of CD4 into the lumen of the ER. The activity of
CADA maps to the cleavable N-terminal SP of hCD4. Moreover,
through SPR analysis we were able to show direct binding of
CADA to the SP of hCD4 and identify this SP as the main target
of our drug. In view of the very high selectivity of CADA for
hCD4, it is most plausible to hypothesize a unique SP as its target.
However, we cannot completely exclude a secondary interaction
of CADA with another target of the translocation machinery. This
could be in line with the suggested bimolecular binding model for
CADA based on data from unsymmetrical CADA analogs and the
3-D quantitative structure-activity relationship (3D-QSAR) study
[47,48]. If CADA interacts with Sec61 (or closely related factor) in
a more unspecific and non-discriminating manner, the final
decision for a substrate to become translocation defective would
then depend on the degree of reduced SP-flexibility by CADA
binding, suggesting that CADA-dependency would mostly rely on
SP-recognition and binding.
Hydrophobic signal sequences, such as SPs, perform several
functions in the biogenesis of secretory and membrane-bound
proteins [26]. Although these hydrophobic sequences may
represent interesting targets for drug design in order to regulate
the expression level of proteins, CADA is the first small-molecule
drug, to our knowledge, known to selectively bind to a SP and
inhibit translocation of a specific protein in a SP-dependent way.
There is precedence for the cyclic heptadepsipeptide HUN-7293
and its derivatives CAM741 and cotransin to down-modulate
vascular cell adhesion molecule 1 (VCAM1) in a signal-sequence-
discriminatory way [49,50]. However, these compounds were
reported to bind to the Sec61 translocon channel and to inhibit the
expression of a subset of secretory and membrane proteins,
including VCAM1 [34,51–53]. In contrast, the expression levels of
a range of cell surface receptors including VCAM1 (Figure 1F)
and CD4 from a different (non-primate) species (Figure 1D), were
not decreased by CADA, which is explained by the interaction of
the drug with a SP of a specific cell surface receptor instead of a
common Sec61 channel. Recently, the cyclic dodecadepsipeptide
valinomycin has been described to selectively destabilize the SP of
hamster prion protein [54]; however, this might be related to the
down-regulation of the luminal chaperone protein BiP involved in
protein translocation, explaining the general apoptosis-inducing
effect of this drug [55]. The toxic, small-molecule eeyarestatin 1
(ESI) has been reported to inhibit co-translational translocation of
a wide-range of receptors, but this compound prevents the transfer
of the nascent polypeptide chain from the membrane-bound SRP
delivery complex to the ER translocon, thus acting more upstream
of CADA and the cyclodepsipeptides and less substrate-selective
[56]. Mycolactone, the virulence factor of Mycobacterium ulcerans
has recently been described to block protein translocation into the
ER, and thus, to prevent secretion of innate cytokines and
expression of important immune-related membrane receptors
[57]. Also, apratoxin A, a natural product from a marine
cyanobacterium prevents co-translational translocation of a
positions of released precursor (open arrowhead) and signal-cleaved (solid arrowhead) polypeptide chains are indicated. The SP of hCD4 but not pPL was
also detected (open circle). Molecular mass is in kDa. (C) Dose response of CADA (mM) on translocation of RNCs as in (B). Graph shows translocation fractions
of the autoradiogram quantified by phosphorimager analysis. (D) Time of addition of CADA. [hCD4]-(7)-pPL nascent chains of 80 residues (80-mers) were
synthesized in the absence of membranes before exposure to RM for targeting. Nascent chains were left untreated (C, control), or were treated with CADA
(15 mM) either administered at the beginning of the synthesis in the translation mixture (R, ribosomes), administered to membranes for pretreatment (M,
microsomes), or applied to the RNC/RM mixture 15 minutes after initiation of targeting but before puromycin release (P, post-targeting). Graph shows
translocation data of three experiments quantified by phosphorimager analysis. NS, not significant. *p,0.01.
doi:10.1371/journal.pbio.1002011.g006
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Figure 7. CADA locks the hCD4 SP in an intermediate inversion conformation in the translocon. (A) Line diagram of the constructs with
an N-terminal extension of the SP lacking (no-Glyc) or containing a diagnostic glycosylation site (N-Glyc). For ease of comparison, the numbering
refers to the non-extended WT hCD4 SP-containing polypeptide. The N-glycosylation site is underlined and the star indicates the N-glycosylated form
of the protein. (B) Autoradiogram of truncated in vitro translated [35S]methionine-labelled [hCD4]-(7)-pPL RNCs with the glycosylation site-containing
extension (N-Glyc). A non-glycosylation control (no-Glyc) is included (every first lane). Nascent chains were synthesized in the presence of RM, with or
without CADA (15 mM). Samples were separated by SDS-PAGE and analyzed by autoradiography. Intact RNCs (NC-tRNA) and N-terminal glycosylated
RNCs (asterisk) are indicated. Notice that CADA strongly inhibited the glycosylation of the 17+71-mer. (C) Same as in (B), but for the puromycin-
treated samples. Equal aliquots of the translated material were left untreated or treated with PK. Released non-processed nascent chains (NC, open
arrowhead), N-terminal glycosylated forms (asterisk) and signal-cleaved C-terminal translocated species (solid arrowhead) are indicated. (D) Fraction
of glycosylated nascent chains in the absence or presence of CADA as in (C), quantified and plotted against chain length (n$3). *p,0.05; **p,0.001.
(E) Fraction of SP-cleaved C-terminal translocated nascent chains in the absence or presence of CADA as in (C), quantified and plotted against chain
length (n$3). *p,0.01; **p,0.001. (F) Schematic of ribosome/translocon complexes showing probable positioning of the SP of hCD4 in absence or
presence of CADA. Star represents N-glycosylation.
doi:10.1371/journal.pbio.1002011.g007
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wide-spectrum of cellular proteins, which may also explain its
cytotoxic nature [58]. Cellular cytotoxicity is a major concern
when using small synthetic drugs; however, cellular viability was
not compromised by CADA and long-term (,1 year) CADA-
treatment of T-cells was achieved, with preservation of CD4 re-
expression following workout.
In conclusion, our findings demonstrate that with cell-perme-
able small synthetic compounds selective SP-binding and subse-
quent translocation inhibition of the associated protein is feasible.
This opens a new field, not only for CD4 related immunomod-
ulation and antiviral intervention, but also for a wide range of cell
surface proteins for which this principle of selective SP-targeted
translocation inhibition should be applicable.
Materials and Methods
Compound
CADA.HCl and MFS105.HCl were synthesized as described
previously [47]. The compounds were dissolved in DMSO and
stored at room temperature in the dark.
Constructs
The pcDNA3 expression vector (Invitrogen) encoding WT
hCD4 was kindly provided by O. Schwartz (Institut Pasteur, Paris,
France). The A2.01/hCD4.426 and A2.01/hCD4-CD8 cell clones
were from C. Devaux (Montpellier, France) and have been
described elsewhere [59]. The pReceiver-M16 vector encoding
mouse CD4-YFP was purchased from Imagenes and the human-
mouse chimera constructs [60] were kindly provided by A. Trkola
(Zurich, Switzerland). Bovine pPL in the pGEM4 vector has been
described previously (plasmid pGEMBP1 [61]). Human and
mouse CD4 were cloned into the pGEM4 vector for in vitro
translation experiments. Fusion constructs were generated by PCR
and cloned into the pGEM4 vector. The human/mouse chimaeric
constructs were generated by incorporating the mouse sequence
into the coding human sequence using PCR overlap extension and
site-directed mutagenesis (Stratagene). The same strategy was used
for the murine/hCD4 and pPL/CD4 chimaeras. For the V5-
tagged CD4 construct [hCD4]-V5sCD4, the simian virus 5 (V5)
epitope (GKPIPNPLLGLD) was inserted in the pcDNA3.1-
hCD4D1D2 plasmid, which contains the coding sequence of the
two N-terminal domains of the hCD4 protein. The V5 sequence
was incorporated at the N-terminus of mature CD4 between
residue 32 and 33 as schematically presented in Figure S3E. Note
that the first two residues of V5 (residue G and K) were already
present in CD4 at positions 31 and 32.
Cell Culture and Cellular Assays
The CD4+ T-cell lines MT-4 and SupT1 were cultured in
RPMI-1640 medium, and Hela, U87, HEK293T, and CHO cells
were cultured in DMEM, supplemented with 10% FCS and
penicillin/streptomycin. Human PBMCs were isolated by density
gradient centrifugation as described previously [18]. For the
monkey PBMCs, blood was collected from cynomolgus macaques
(Macaca fascicularis) as described elsewhere [62]. Murine PBMCs
were isolated from blood collected from Balbc mice. Stable
transfections of U87 cells were performed with FuGENE 6
Transfection Reagent (Roche Diagnostics), and transient
transfections of HEK293T cells were performed with PolyJet in
vitro transfection reagent (Tebu-Bio), in accordance with the
manufacturer’s instructions. Western blot analysis of cell lysates
was performed in accordance with standard protocols. Mouse
monoclonal antibodies anti-hCD4 (clone SK3, BD Biosciences),
anti-clathrin heavy chain (clone 23, BD Biosciences), anti-THE
SV5-tag mAb (Genscript), anti-actin (Abcam ab3280), and a HRP-
conjugated goat anti-mouse antibody (Dako) were used for
detection.
For the cytosolic CD4 precursor rescue experiments, HEK293T
cells were transfected with a mixture of 500 ng pcDNA3.1-V5-
hCD4D1D2 plasmid DNA and 2 ml lipofectamine 2,000 (Invitro-
gen). Six hours after transfection, growth medium was removed
and replaced with fresh medium containing 10 or 2 mM CADA
and/or 200 nM MG132 (Sigma). After a 22 hour incubation in
the presence of the compounds, cells were washed with ice-cold
PBS and lysed in ice-cold lysis buffer (25 mM Tris, 150 mM NaCl,
1 mM EDTA, 1% NP-40, 5% glycerol, pH 7.4), supplemented
with 0.4 mM PMSF (Fluka) and Complete protease inhibitor
cocktail (Roche).
Flow Cytometry
Flow cytometric analysis of surface receptor expression was
performed as described previously [18]. All FITC-, PE-, PerCp-,
or APC-labelled mAbs were from BD Biosciences. Data were
acquired with a FACSCalibur flow cytometer (BD Biosciences)
and the CellQuest software (BD Biosciences). Data were analyzed
with the FLOWJO software (Tree Star). Down-modulation of
CD4 was evaluated by the decrease in fluorescence intensity on
CADA-treated cells relative to matched, untreated cells stained for
CD4. To calculate the efficiency of CADA on CD4 down-
modulation, the median fluorescence intensity (MFI) for CD4
labelling for each sample was expressed as a percentage of the MFI
of control cells (after subtracting the MFI of the unstained control
cells).
Metabolic Labelling
Pulse-labelling of CD4 was performed on CD4+.CHO cells
preincubated for 45 min at 37uC with CADA (16 mM) in medium
lacking methionine, cysteine, and serum. After being pulsed with
0.75 mCi ml21 [35S]methionine/cysteine for 30 min, cells were
chased by replacing the radiolabel with pre-warmed medium
containing 1 mM cysteine and 1 mM methionine. At the end of
the chase this medium was replaced by ice-cold DMEM. Cells
were kept on ice and lysed in NP-40 buffer (2% NP-40, 20 mM
Tris [pH 7.8], 150 mM NaCl, 2 mM MgCl2), and cell lysates
(separated from nuclei and debris) were immunoprecipitated for
CD4 as described [63]. Proteins were analyzed by SDS-PAGE and
autoradiography.
Protein Synthesis in Different Cellular Compartments
Cells were pretreated with CADA (5 mM) or DMSO for 1 h
before starvation in Met/Cys free medium with CADA, DMSO,
or 50 mg/ml CHX (Sigma). Cells were pulsed with 0.022 mCi
ml21 [35S]methionine/cysteine EasyTag Protein Labeling mix
(Perkin Elmer) for 30 min, washed twice with PBS, and incubated
in fresh medium without serum for 90 min. After collection of the
supernatant, cells were washed in ice-cold PBS and then either
lysed in ice-cold lysis buffer (25 mM Tris, 150 mM NaCl, 1 mM
EDTA, 1% NP-40, 5% glycerol, pH 7.4) supplemented with
0.4 mM PMSF and protease inhibitor cocktail, or separated into
cytosolic and membrane fractions. To collect the cytosolic
proteins, cells were permeabilized with digitonin buffer (20 mM
Tris, 150 mM NaCl, 2 mM MgCl2, 0.03% digitonin, pH 7.8,
supplemented with 0.4 mM PMSF and protease inhibitor cocktail).
Permeabilized cells were then washed in digitonin buffer and
further lysed in ice-cold lysis buffer (25 mM Tris, 150 mM NaCl,
1 mM EDTA, 1% NP-40, 5% glycerol, pH 7.4, supplemented
with 0.4 mM PMSF and protease inhibitor cocktail). To isolate
glycosylated proteins, total cell lysates or digitonin-resistant
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membrane fractions were further incubated with Concanavalin A
(Vector Laboratories) agarose beads overnight at 4uC by gentle
rotation.
Cell-Free Translation
Full length cDNAs and truncated CD4-pPL nascent chains
generated by PCR were transcribed in vitro using T7 RNA
polymerase, and translated in rabbit reticulocyte lysate (Promega)
in the presence of [35S]methionine (Perkin Elmer). Translations
were performed at 25uC for 45 min (full length) or for 25 min
(truncated) in the presence or absence of mammalian pancreatic
microsomes (RMs). Digestion with Proteinase K (Roche) was
performed on ice for 30 min and stopped by the addition of
phenylmethylsulfonyl fluoride (PMSF; Thermo Fisher Scientific).
Release of the nascent chains (NCs) from the targeted ribosome
was induced by treatment with 2 mM puromycin for 10 min at
25uC. NCs were isolated by sedimentation at 4uC and pellets were
dissolved in SDS sample buffer for analysis by SDS-PAGE. For the
quantitative analysis of translocation experiments we used a
Cyclone Plus phosphorimager (Perkin Elmer) with accompanying
software.
For the time-of-addition experiments, [hCD4]-(7)-pPL nascent
chains of 80 residues were synthesized in rabbit reticulocyte lysate
by translating the mRNA for 20 min at 25uC. Translation was
done in the absence of RM, and the translation mixture was left
untreated (C, control) or was treated with CADA (15 mM) from
the beginning of the translation reaction (R, ribosomes). In the
mean-time, some RMs were pretreated with CADA (15 mM).
After 20 min of translation, the untreated control sample was split
in three aliquots. Next, one aliquot of control sample and the
CADA-sample were given untreated RMs. The CADA-pretreated
RMs were administered to the second control sample (M,
microsomes). The third control sample received untreated RMs.
All samples were then incubated for 10 min on ice and 5 min at
25uC. Finally, CADA was administered to the third control sample
(P, post-targeting), and all samples were further incubated for
5 min at 25uC, before treatment with puromycin. NCs were
isolated by sedimentation at 4uC and pellets were dissolved in SDS
sample buffer for analysis by SDS-PAGE.
Surface Plasmon Resonance Analysis
Chemically synthesized SPs (PEPperPRINT) were captured on
a streptavidin-coupled C1 sensor chip (GE Healthcare). The
amino acid sequence of the SP was: MNRGVPFRH-
LLLVLQLALLPAATQGKKVVLGKK-PEG11-K-biotin for
hCD4, MCRAISLRRLLLLLLQLSQLLAVTQGKTLVLGKE-
PEG11-K-biotin for mCD4, and MDSKGSSQKGSRLLL-
LLVVSNLLLCQGVVSTPVCPNGP-PEG11-K-biotin for pPL.
The chip density was between 84 and 215 resonance units (RUs).
A reference flow cell was used as a control for non-specific binding
and refractive index changes. All interaction studies were
performed at 25uC on a Biacore T200 instrument (GE
Healthcare). The compound CADA was diluted in HBS-P
(10 mM HEPES, 150 mM NaCl, and 0.05% surfactant P20
[pH 7.4]) supplemented with 5% DMSO. Signal recognition
particle (tRNA Probes) was included as a positive control. Samples
were injected for 2 min at a flow rate of 30 ml/min and the
dissociation was followed for 2 min.
Statistics
All data are presented as means with standard deviations (SD),
unless otherwise stated. Two-tailed Student’s t test was used to
determine statistical significance as calculated with GraphPad
software. For the flow cytometric data, statistical analysis was done
on the background-corrected MFI values between compound
treated and control (without compound) samples.
Supporting Information
Figure S1 CADA dose-dependently down-modulates
hCD4 fusion protein. (A) CHO cells, stably expressing CD4-
YFP (hCD4 fused at its COOH-terminus to the YFP), were treated
for 24 h with a serial 1:10 dilution of CADA. Cells were collected,
stained with anti-CD4 mAb, and analyzed by flow cytometry for
receptor expression by simultaneous detection of CD4 and YFP.
One representative experiment is shown. (B) Cell lysates of (A)
were analyzed by immunoblotting for CD4-YFP fusion protein
(,80 kDa) with anti-GFP or anti-clathrin antibodies. A non-
transfected control is included (first lane). Molecular mass is in
kDa. (C) CADA does not affect WT CCR5 receptor expression.
Freshly isolated primary T-cells from two different donors were
incubated with CADA for 3 days, stained for CCR5, and analyzed
by flow cytometry for receptor expression. Bars represent the
mean fluorescent intensities (MFI) for CCR5 of 10,000 analyzed
cells. (D) Scheme of the CD4-CCR5 fusion protein, composed of
the NH2-terminal part of hCD4 fused to the seven TM domain G
protein coupled chemokine receptor CCR5. (E) HEK293T-cells
expressing hCD4-CCR5 (construct shown in (D)) were treated for
48 h with control medium or CADA and stained with anti-CD4 or
anti-CCR5 antibodies to determine surface expression levels of
mutant CD4 by flow cytometry. Graph shows relative receptor
expression levels of CADA-treated cells as compared to non-
treated controls. (F) CADA does not affect mRNA steady state
levels of hCD4. Three different cell lines (U87.CD4, CHO.CD4,
and SupT1) were incubated with CADA for 24 h and subjected to
real-time reverse transcription (RT)-PCR for CD4. The results
were analyzed in terms of CT values. The triplicate values are
shown for control and CADA-treated samples. In parallel, cell
surface CD4 was determined by flow cytometry, confirming a
profound down-modulation of surface CD4 with CADA (.80%
reduction in CD4 protein levels).
(EPS)
Figure S2 CADA does not generally target membrane
and secreted proteins. (A) U87 cells were pretreated with
CADA (5 mM) or DMSO for 1 h before starvation for 30 min in
Met/Cys free medium with CADA, DMSO, or 50 mg/ml CHX.
Cells were pulsed for 30 min, washed, and incubated in fresh
medium without serum for 90 min. After collection of supernatant
proteins (Media) cells were lysed in NP-40 buffer to obtain total
cell lysate (Lysate). Glycosylated proteins were isolated from total
lysate with Concanavalin A (ConA) agarose beads (Glycosylated).
(B) Same as in (A) for SupT1 cells. Where indicated, pretreated
cells were activated with 2 mg/ml phytohaemagglutinin (PHA) for
1 h before they were incubated in starvation medium. The
secreted protein fraction of a second experiment in which the cells
responded to the same PHA-stimulus more effectively is included.
(EPS)
Figure S3 CADA inhibits co-translational translocation
of an hCD4 SP-containing control protein. To support our
findings that CADA acts solely through the SP-containing N-
terminus of hCD4, we generated a cDNA encoding a non-CD4
related soluble protein with the signal sequence and seven
N-terminal residues of hCD4 attached to its N-terminus. For ease
of detection, YFP was selected as reporter protein. (A) Schematic
representation of the YFP construct used. Numbers represent the
corresponding amino acids of the pre-protein. The N-terminal SP
is indicated by a black rectangle. (B) Dose-response curve showing
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the effect of CADA on YFP expression in cellulo. HEK293T cells
were transiently transfected with the expression plasmid and left
either untreated or treated with CADA for 48 h. YFP levels were
determined by flow cytometry and normalized to non-treated
controls (n=5). IC50 value for CADA is 1.28 mM. (C) Transcripts
encoding the YFP construct were translated in vitro in rabbit
reticulocyte lysate in the presence of [35S]methionine and, where
indicated, RMs and/or CADA (15 mM). Samples were separated
by SDS-PAGE and analyzed by autoradiography. The position of
precursor and signal-cleaved species is indicated. (D) HEK293T
cells were transiently transfected with the expression plasmid and
left either untreated or treated with CADA (10 mM). The
proteasome inhibitor MG132 (5 mM) was added 5 h post-
transfection and cells were incubated for another 18 h. Next, cell
lysates were analyzed by immunoblotting with anti-GFP or anti-
clathrin antibodies. In the right panel, the input of the CADA
sample is enhanced in order to visualize the rescued precursor
protein [hCD4]-(7)-YFP. (E) Schematic representation of the V5-
tagged CD4 construct used in Figure 4F. Numbers represent the
corresponding amino acids of the pre-protein. The N-terminal SP
is indicated by a black rectangle. The simian virus 5 (V5) epitope
(GKPIPNPLLGLD) was incorporated at the N-terminus of
mature CD4 between residue 32 and 33. Note that the first two
residues of V5 (residue G and K) were already present in CD4 at
positions 31 and 32.
(EPS)
Figure S4 CADA specifically binds to the SP of human
CD4 in a dose-dependent way. (A) Dose-dependent binding
of CADA to the SP of hCD4. Peptides composed of the signal
sequence and eight N-terminal residues of mature CD4, plus a
PEG11 linker and a biotinylated lysine at the C-terminus, were
chemically synthesized and captured on a streptavidin C1 chip for
SPR analysis. The chip density was 104 resonance units (RUs).
Graph shows binding to SP of hCD4 for increasing doses of
CADA (mM). Insert gives corresponding RU values. (B) As in (A),
but for the binding of SRP to the SP of mouse CD4. The chip
density was 130 resonance units (RUs). Graph shows dose
response of SRP (nM) to mouse CD4 SP. (C) Dose-dependent
binding of CADA (black solid and dotted lines) to the SP of hCD4
(left panel) but not to the bovine pPL SP (right panel). The chip
density was 123 RUs for hCD4 and 215 RUs for pPL. For pPL,
the binding of 100 mM MFS105 was also tested (red line). (D)
Repeat experiment as presented in Figure 5C. The chip density
was 121 RUs. (E) Chemical structure of MFS105 (MFS),
molecular weight (MW)= 466.
(EPS)
Figure S5 CADA interacts primarily with the hydropho-
bic H-region of the human CD4 signal peptide. (A) In vitro
translocation of the human-murine chimaera from Figure 5D.
Translation and translocation of the CD4 constructs were
performed as described in the legend to Figure 4C and 4D. One
representative gel out of two is shown. (B) Translocation data of (A)
were quantified by phosphorimager analysis and the translocation
efficiencies as normalized to control were calculated (mean values
of two experiments). The IC50 values of CADA for each construct
are included for the in vitro translocation experiments. (C)
Insertion of the hydrophobic H-region of hCD4 into the SP of
mouse CD4 results in sensitivity to CADA. The sequences of the
SP of WT mouse CD4 and the murine-human chimaera are
indicated at the top of the graph. Graph shows the flow cytometry
analysis of HEK293T cells transiently transfected with the
expression plasmids of WT murine CD4 and murine-human
chimaera left either untreated or treated with CADA for 48 h.
Cells were collected and stained for hCD4. CD4 expression levels
were normalized to non-treated controls (n=3). IC50 value for
CADA=2.45 mM. *p,0.01. (D) Insertion of the hydrophobic H-
region of hCD4 into the SP of bovine pPL results in sensitivity to
CADA. The sequences of the SP of WT pPL and the pPL-human
chimaera are indicated at the top of the graph. Graph shows the in
vitro translocation efficiencies as described in (A) and (B). pPL
translocation levels were normalized to non-treated controls (n$
2). *p,0.01.
(EPS)
Figure S6 The alpha-helix terminator Proline 20 (P20)
in the SP of hCD4 is necessary but not sufficient for
CADA sensitivity. (A) Occurrence of proline residues in
different SPs. Clustal W Multiple alignment of SP sequences,
compared to the hCD4 SP. (B) The Clustal W Multiple alignment
was used to create a weblogo (WebLogo 3.4) where the first
position corresponds to M1 of hCD4. There is no dominant
occurrence of proline residues at the C-terminus of the
hydrophobic core region of SPs. (C) Different proline mutants
were tested for CADA sensitivity. HEK293T cells were transiently
transfected with the expression plasmids and left either untreated
or treated with 10 mM CADA for 48 h. Cells were collected and
stained for hCD4. CD4 expression levels were normalized to non-
treated controls. The SP sequences of the six constructs used are
listed in the same order as presented in the graph from left to right.
(EPS)
Figure S7 CADA inhibits co-translational translocation
of hCD4-pPL nascent chains. (A) Autoradiogram of truncated
in vitro translated [35S]methionine-labelled [hCD4]-(7)-pPL.
Nascent chains of increasing length were synthesized in the
presence of RM, with or without CADA (15 mM). Next, samples
were treated with puromycin to release the nascent chains from
ribosomes. Equal aliquots of the translated material were left
untreated or treated with PK. Samples were separated by SDS-
PAGE and analyzed by autoradiography. Intact peptidyl-tRNA
bands (arrow), released nascent chains (open arrowhead), signal-
cleaved species (solid arrowhead), and SPs (open circle) are
indicated. Molecular mass is in kDa. Note that for the 102-mers,
addition of RM already resulted in some SP-cleaved species (lane
21). (B) Fraction of translocated nascent chains (after puromycin
release) in the absence or presence of CADA (as in (A)) quantified
and plotted against chain length (means 6 standard deviation
[SD]; n$3). Note that the optimal chain length for efficient SP-
cleavage and C-terminal translocation is 80 residues. (C) Inhibition
by CADA of the translocation of [hCD4]-(7)-pPL nascent chains
from (B). The fraction of translocated nascent chains was
quantified for CADA samples and compared to that of the
untreated controls in order to determine the percentage
translocation-inhibition for CADA (means 6 SD; n$3).
(EPS)
Figure S8 Effect of CADA on the translocation of N-
terminal extended N-glycosylation tagged proteins. (A)
Autoradiogram of in vitro translated N-tagged [hCD4]-(7)-pPL
full length constructs represented in Figure 7A. Translation was as
described in the legend to Figure 4D. The positions of full length
precursor (open arrowhead) and signal-cleaved translocated (solid
arrowhead) species are indicated. N-glycosylated species are
almost non-existing because the SP (that contains the
N-glycosylation site) is cleaved off from the pre-protein during
translocation. (B) Deglycosylation with Endo H of N-terminal
glycosylated 17+62-mers from Figure 7C. (C) CADA dose-
dependently inhibits both the N-terminal glycosylation and the
C-terminal translocation with SP-cleavage of the 17+80-mers.
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Same as in Figure 7B and 7C, except that a 1:10 serial dilution of
CADA was used. (D) Graph shows translocation data of (C)
quantified by phosphorimager analysis. (E) Intact nascent chains
(NC-tRNA) from Figure 7B were exposed to PK in the absence or
presence of 0.5 M NaCl. Note that only the control samples of the
17+71-mers were high-salt resistant, whereas in the presence of
CADA these nascent chains became high-salt sensitive.
(EPS)
Figure S9 N-terminal N-glycosylation is dependent on
extension length. (A) Extension of the SP N-terminus requires
minimum 17 residues for efficient N-terminal glycosylation.
Schematic representation of the different constructs with a
diagnostic glycosylation site at the N-terminus of the SP. Construct
N8 is a G4S mutant of WT hCD4 SP with a NRS glycosylation
site. The other constructs contained an N-terminal extension of
the SP. The residues of the SP of hCD4 are in black, whereas
those of the inserted tag are depicted in grey. The glycosylation
sites are in italic and underlined. The numbering (N8, N13, N18,
and N24) refers to the position of the asparagine residue of the
glycosylation site, relative to the N-terminal end of the H-domain
of the SP (leucine residue, L10 of WT hCD4 SP). (B)
Autoradiogram of truncated in vitro translated [35S]methionine-
labelled [hCD4]-(7)-pPL RNCs in the presence of RM. All
constructs were C-terminal truncated at the same residue, i.e.,
residue 33 of the mature protein (resulting in the 58-mer for WT
[hCD4]-(7)-pPL). Intact RNCs (NC-tRNA, arrow) and N-terminal
glycosylated RNCs (asterisk) are indicated. (C) Fraction of N-
terminal glycosylated nascent chains (after puromycin release) for
the constructs from (A). Fractions are quantified and plotted
against chain length. Here, x represents the variable length of the
N-terminal extension, with x= 0 for N8, x = 7 for N13, x = 10 for
N18, and x= 17 for N24. (D) Same as in (C), but for the fraction of
C-terminal translocated (with SP-cleavage) nascent chains. Note
that for all constructs optimal chain length for efficient C-terminal
translocation is x+80 residues. (E) CADA does not inhibit signal
peptidase activity. Signal peptidase was extracted from micro-
somes and used for in vitro cleavage of leader sequences from
control bovine pre-prolactin (pPL, right panel) and [hCD4]-(7)-
pPL (CD4, left panel) in the absence or presence of CADA
(15 mM). The positions of full length precursor (open arrowhead)
and signal-cleaved (solid arrowhead) species are indicated. In lane
2, intact membranes (RM) were added to the translation mixture
to determine normal SP cleavage. In lanes 3–5, full length protein
was first translated in vitro and denatured in SDS buffer before
administration of the extracted signal peptidase (lanes 4 and 5).
(EPS)
Data S1 Data for graphs in Figures 1-7 and Figures S1-S9.
(XLSX)
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